

ASX Announcement

15 April 2026

Acquisition of Fukang OTC Pharmacy

15 April 2026. Hong Kong, China. Xenitra Limited (ASX:XEN) (the “Company”) is excited to update shareholders that it has acquired Hong Kong Fukang Trading Co., Limited (“Fukang”).

Xenitra specialises in fast-moving consumer goods (“FMCG”), nutraceuticals and OTC Medicine products that are sold through established distribution channels spanning Business-to-Business (B2B) wholesale, retail distribution and all major ecommerce platforms in Asia with sales of more than \$70m since 2024.

The Company gained authorisation for a Hong Kong pharmaceutical wholesale license and to launch its cross border over the counter (“OTC Medicine”) business on 18 December 2025 (see also ASX announcement of that date).

The Company has now acquired 100% of the shares in Fukang, as well as the required assets to operate the OTC Medicines business including:

- **Hong Kong Pharmaceutical License PW-2024-00189;**
- Hong Kong pharmaceutical license premise lease;
- JD.com Store Deposit;
- Class 35 Trademark/Trademark Registration No.: 306786802;
- warehouse Logistics Service Deposit with Hong Kong Kanghong Pharmaceutical Group Co., Ltd;
- inventory on hand; and
- total cost for the shares, deposits and the assets acquired of ¥469,243.

The acquisition enables the Company to assume the operations of Fukang and will enable meaningful expansion in the offering of OTC medicine products to the China market under the Hong Kong Pharmaceutical licence and the Fukang online eCommerce shopfronts.

Chairman, Anthony Noble said:

“The acquisition now fully operationalises our OTC business in Hong Kong and in China. This is a meaningful step forward in this critical business unit. Importantly, having this Hong Kong Pharmaceutical Licence in place will allow the Company to bring more new products into the China market seamlessly leveraging established shopfronts, customer databases and a highly experienced team on the ground. We are delighted to welcome the Fukang team into Xenitra and are excited by the opportunities for product expansion that this acquisition has enabled.”

This release has been approved by the board of directors.

About Xenitra Limited

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals and over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra is an established brand acceleration partner for western brands entering the Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity.

Forward Looking Statements

This announcement may contain forward-looking statements, including statements regarding: plans, strategies and objectives of management; anticipated revenue, products, and stores; operating costs; Chinese tourism; Governmental policies and preferences (both Australian and Chinese). Forward-looking statements can be identified by the use of terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue', 'annualised' or similar words. These statements discuss future expectations concerning the results of operations or financial condition, or condition or provide other forward-looking statements. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements. Except as required by applicable regulations or by law, the Group does not undertake any obligation to publicly update or review any forward-looking statements, whether as a result of new information or future events. Past performance cannot be relied on as a guide to future performance.